Loading viewer...
investor_presentation
Format: PDF investor_presentation
Q3 2020 Earnings Kevin Hrusovsky Chairman & CEO November 5, 2020
November 5, 2020Forward -Looking Statements & Non -GAAP Financial Measures
This presentation contains forward -looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such
as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expres sions referencing
future events, conditions or circumstances) are intended to identify forward -looking statements. Forward -looking statements are based on
Quanterix’ expectations and assumptions as of the date hereof. Each of these forward -looking statements involves risks and uncertainties.
Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward- looking statements in this press
release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections
contained therein. Except as required by law, Quanterix assumes no obligation to update any forward -looking statements contained herein to
reflect any change in expectations, even as new information becomes available.
To supplement the Company’s financial statements presented on a GAAP basis, the Company has provided certain non- GAAP financial
measures. Management uses these non- GAAP measures to evaluate the Company’s operating performance in a manner that allows for
meaningful period -to-period comparison and analysis of trends in its business. Management believes that such measures are import ant in
comparing current results with prior period results and are useful to investors and financial analysts in assessing the Company’ s operating
performance. The non- GAAP financial information presented here should be considered in conjunction with, and not as a substitute for the
financial information presented in accordance with GAAP. Investors are encouraged to review the reconciliation of these non- GAAP
measures to their most directly comparable GAAP financial measures set forth in the appendix of this presentation.
Q3 2020 Earnings - Nov. 5, 2020 2Today’s Agenda
I. Strategic and Financial Progress –Kevin Hrusovsky –Chairman, CEO
i. Q3 2020 Strategic Advances & Highlights
ii. Vision and Strategy –Executional / Aspirational value creation
II. Financial Report –Amol Chaubal –CFO
Q3 2020 Earnings - Nov. 5, 2020 3Continuing our journey into 2020, despite COVID -19 Headwind
Further pivoting our focus to COVID & Neuro to drive breakout performance
PUBLICATIONS* MARKERS*
18 1920ytd104206409677985
Oncology*Infectious Diseases
20ytd19190259322368* Cumulative
* Incl. Immunology & Inflammation
Q3 2020 Earnings - Nov. 5, 2020 41310213564 65
YTDAlzheimer’s Publications Accelerating
Preview truncated — download the full document for the complete content.
investor_presentation
24 Pages
investor_presentation
63 Pages
Immutep